Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $175

Benzinga Newsdesk www.benzinga.com Positive 59.6%

Neg 0% Neu 0% Pos 59.6%

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $160 to $175.